CADL — Candel Therapeutics, Inc. stock price, charts and financials

Latest market price

10.07

+0.06+0.60%

Overview Short InterestFilings

CADLQT87Candel Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

10.07+0.60%

News

Up 0.6% — Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 (globenewswire.com).

Medium confidence

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

IOVA+6.14%$4.32 FTRE-1.20%$18.94 SLS+12.09%$11.22 URGN+0.92%$38.59 MESO+2.12%$14.47 TSHA-1.37%$5.78 TYRA+0.50%$32.04 AUPH-2.08%$14.57

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	13.79%	Shs Outstand	73.27M	Perf Week	4.71%

Market Cap	733.43M	Forward P/E	-	EPS next Y	-0.69	Insider Trans	6.87%	Shs Float	56.81M	Perf Month	1.32%

Enterprise Value	540.40M	PEG	0.21	EPS next Q	-	Inst Own	-	Short Float	22.82%	Perf Quarter	61.97%

Income	-63.96M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	6.11	Perf Half Y	68.80%

Sales	0.00	P/B	4.52	EPS next Y	25.52%	ROA	-26.95%	Short Interest	12.96M	Perf YTD	77.17%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-60.42%	52W High	11.43 -11.88%	Perf Year	52.36%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-28.89%	52W Low	4.38 130.11%	Perf 3Y	770.43%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	5.94% 5.97%	Perf 5Y	-

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	43.68%	Oper. Margin	0.00%	ATR (14)	0.60	Perf 10Y	-

Dividend Ex-Date	-	Quick Ratio	28.05	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	55.24	Recom	2.10

Dividend Gr. 3/5Y	-	Current Ratio	28.05	EPS Q/Q	-207.69%	SMA20	2.05%	Beta	1.83	Target Price	22.50

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	9.30%	Rel Volume	0.58	Prev Close	10.01

Employees	55	LT Debt/Eq	0.02	Earnings	Aug 13	SMA200	53.13%	Avg Volume	1.94M	Price	10.07

IPO Date	Jul 27, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	52.68% -	Net Debt/EBITDA	3.84	Volume	1,115,669	Change	0.60%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jul-29-26	Reiterated	H.C. Wainwright	Buy	$23
Jul-13-26	Initiated	Stifel	Buy	$22
Oct-27-25	Initiated	Stephens	Overweight	$15
Sep-03-25	Downgrade	B of A Securities	Buy → Neutral

Latest News

Today

Today08:05AM

Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026globenewswire.com

Jul-29-26

Jul-29-2608:05AM

Candel Therapeutics to Present at Canaccord Genuity's 46th Annual Growth Conference in Bostonglobenewswire.com

Jul-13-26

Jul-13-2605:53AM

Stifel Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $22Benzinga

Jul-08-26

Jul-08-2604:05PM

Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jul-04-26

Jul-04-2602:06AM

Candel Therapeutics: An Overlooked Late-Stage Biotech With Real PotentialSeekingAlpha

Jul-01-26

Jul-01-2604:05PM

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Jun-30-26

Jun-30-2608:05AM

Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitorsglobenewswire.com

Company

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019
Total Revenue	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0
Gross Profit	0	0	0	0	0	0	0
Selling, General and Administrative Excl. Other	18	14	14	14	11	5	3
Research and Development	30	19	25	21	15	9	7
Other Operating Expense	0	0	-1	0	-1	0	-1
Operating Income	-48	-33	-38	-35	-25	-14	-9
Interest Expense	2	2	3	2	0	0	0
Unusual Expense	—	—	—	—	—	—	—
Non-Operating Income (Expense)	12	-20	3	18	-11	-4	1
Net Income Before Taxes	-38	-55	-38	-19	-36	-18	-8
Income Taxes	0	0	0	0	0	0	0
Consolidated Net Income	-38	-55	-38	-19	-36	-18	-8
Net Income From Continuing Operations	-38	-55	-38	-19	-36	-18	-8
Net Income	-38	-55	-38	-19	-36	-18	-8
EPS (Recurring)	-0.72	-1.74	-1.31	-0.10	-1.26	-1.18	-0.43
EPS (Basic, Before Extraordinaries)	-0.72	-1.74	-1.31	-0.10	-1.26	-1.18	-0.43
EPS (Diluted)	-0.72	-1.74	-1.31	-0.10	-1.26	-1.18	-0.43
EBITDA	-35	-52	-34	-16	-24	-13	-8
Other After Tax Adjustments	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—
Shares Outstanding	53	32	29	29	29	19	19
Market Capitalization	299	278	43	52	227	—	—
Operating Lease Expense	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barone Francesca	Chief Scientific Officer	Jun 29 '26	Sale	10.06	23,447	235,769	77,362	Jul 01
Tyagarajan Seshu	Chief Technology Officer	Jun 29 '26	Sale	10.02	7,000	70,151	83,865	Jul 01
Manning Paul B	Director	Feb 23 '26	Buy	5.45	550,458	2,999,996	2,763,527	Feb 26
Nichols William Garrett	Chief Medical Officer	Jul 28 '25	Option Exercise	1.29	937	1,209	53,430	Jul 30
Nichols William Garrett	Chief Medical Officer	Jul 28 '25	Sale	6.98	937	6,540	52,493	Jul 30
Nichols William Garrett	Chief Medical Officer	Jun 30 '25	Sale	5.04	781	3,936	52,493	Jul 02
Nichols William Garrett	Chief Medical Officer	Jun 30 '25	Option Exercise	1.29	781	1,007	53,274	Jul 02
Tak Paul Peter	Chief Executive Officer	Mar 19 '25	Sale	9.00	400	3,601	225,740	Mar 20
Nichols William Garrett	Chief Medical Officer	Mar 18 '25	Option Exercise	1.90	18,489	35,127	97,809	Mar 20
Nichols William Garrett	Chief Medical Officer	Mar 18 '25	Sale	8.76	45,316	396,995	52,493	Mar 20
Barone Francesca	Chief Scientific Officer	Mar 18 '25	Option Exercise	1.55	18,000	27,900	128,673	Mar 20
Barone Francesca	Chief Scientific Officer	Mar 18 '25	Sale	8.76	32,146	281,673	96,527	Mar 20
Tak Paul Peter	Chief Executive Officer	Mar 18 '25	Sale	8.77	25,772	226,023	226,140	Mar 20
Tyagarajan Seshu	Chief Technology Officer	Mar 17 '25	Option Exercise	1.29	20,000	25,800	116,790	Mar 20
Schoch Charles	See Remarks	Mar 17 '25	Sale	8.83	5,000	44,169	38,038	Mar 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.